Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ads For Aleve, Tylenol Arthritis Lines Launch In Wake Of NSAID Warning 

This article was originally published in The Tan Sheet

Executive Summary

Bayer and McNeil are taking different marketing approaches for their OTC arthritis analgesics in ads aimed at consumers concerned about NSAID safety
Advertisement

Related Content

Tylenol Ads Spotlight OTC NSAID Class Link To COX-2 Drugs
Tylenol Ads Spotlight OTC NSAID Class Link To COX-2 Drugs
FDA’s Ganley “Disappointed” By Competitive Pain Reliever Marketing
FDA’s Ganley “Disappointed” By Competitive Pain Reliever Marketing
Naproxen May Be “Exception” To NSAID Rule, But Data Is Lacking – FDA
FDA Determines A “Class Effect” Is In Play For All NSAIDs
FDA Determines A “Class Effect” Is In Play For All NSAIDs

Topics

Advertisement
UsernamePublicRestriction

Register

PS098102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel